The DOI matches its Crossref record; 170 of the 170 references it cites were found in a registry or an index.
Therapeutic Implications of Tumor Microenvironment in Lung Cancer: Focus on Immune Checkpoint Blockade
Open accessAbstract
In the last decade, the treatment of non-small cell lung cancer (NSCLC) has been revolutionized by the introduction of immune checkpoint inhibitors (ICI) directed against programmed death protein 1 (PD-1) and its ligand (PD-L1), or cytotoxic T lymphocyte antigen 4 (CTLA-4). In spite of these improvements, some patients do not achieve any benefit from ICI, and inevitably develop resistance to therapy over time. Tumor microenvironment (TME) might influence response to immunotherapy due to its prominent role in the multiple interactions between neoplastic cells and the immune system. Studies investigating lung cancer from the perspective of TME pointed out a complex scenario where tumor angiogenesis, soluble factors, immune suppressive/regulatory elements and cells composing TME itself participate to tumor growth. In this review, we point out the current state of knowledge involving the relationship between tumor cells and the components of TME in NSCLC as well as their interactions with immunotherapy providing an update on novel predictors of benefit from currently employed ICI or new therapeutic targets of investigational agents. In first place, increasing evidence suggests that TME might represent a promising biomarker of sensitivity to ICI, based on the presence of immune-modulating cells, such as Treg, myeloid derived suppressor cells, and tumor associated macrophages, which are known to induce an immunosuppressive environment, poorly responsive to ICI. Consequently, multiple clinical studies have been designed to influence TME towards a pro-immunogenic state and subsequently improve the activity of ICI. Currently, the mostly employed approach relies on the association of “classic” ICI targeting PD-1/PD-L1 and novel agents directed on molecules, such as LAG-3 and TIM-3. To date, some trials have already shown promising results, while a multitude of prospective studies are ongoing, and their results might significantly influence the future approach to cancer immunotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Robust enumeration of cell subsets from tissue expression profiles
Newman, A. M., Liu, C. L., Green, M. R., Gentles, A. J., Feng, W., Xu, Y., Hoang, C. D., Diehn, M., & Alizadeh, A. A. (2015) · Nature Methods · doi:10.1038/nmeth.3337 · Cited by 13,224
Inferring tumour purity and stromal and immune cell admixture from expression data
Yoshihara, K., Shahmoradgoli, M., Martínez, E., Vegesna, R., Kim, H., Torres-Garcia, W., Treviño, V., Shen, H., Laird, P. W., Levine, D. A., et al. (2013) · Nature Communications · doi:10.1038/ncomms3612 · Cited by 9,778 · cited 2×
“number of computational algorithms have been developed for the prediction of non-cancer cell infiltration (Table 1) (75, 79, 82, 85, 86, 88, 89).”
BackgroundOncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607 · cited 1×
“In the randomized, phase III KEYNOTE 189 and KEYNOTE 407 trials, which involved patients with advanced non-squamous and squamous NSCLC, respectively, the addition of pembrolizumab to platinum-based chemotherapy resulted in improved outcomes in terms of response and survival over chemotherapy alone (5, 6).”
BackgroundType, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474 · cited 1×
“2 Immunosuppression Frequently, TME is characterized by the presence of cells endowed with immune suppressive activities and an association with resistance to ICI has been reported, in cancer (10, 30, 31).”
BackgroundTIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells
Li, T., Fan, J., Wang, B., Traugh, N., Chen, Q., Liu, J. S., Li, B., & Liu, X. S. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-0307 · Cited by 5,913
The Immune Landscape of Cancer
Thorsson, V., Gibbs, D. L., Brown, S. D., Wolf, D., Bortone, D. S., Ou Yang, T.-H., Porta-Pardo, E., Gao, G. F., Plaisier, C. L., Eddy, J. A., et al. (2018) · Immunity · doi:10.1016/j.immuni.2018.03.023 · Cited by 5,870
Radiomics: the bridge between medical imaging and personalized medicine
Lambin, P., Leijenaar, R. T. H., Deist, T. M., Peerlings, J., de Jong, E. E. C., van Timmeren, J., Sanduleanu, S., Larue, R. T. H. M., Even, A. J. G., Jochems, A., et al. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.141 · Cited by 5,688
Cancer immunoediting: from immunosurveillance to tumor escape
Dunn, G. P., Bruce, A. T., Ikeda, H., Old, L. J., & Schreiber, R. D. (2002) · Nature Immunology · doi:10.1038/ni1102-991 · Cited by 5,393
TIMER2.0 for analysis of tumor-infiltrating immune cells
Li, T., Fu, J., Zeng, Z., Cohen, D., Li, J., Chen, Q., Li, B., & Liu, X. S. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa407 · Cited by 5,209
Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach
Aerts, H. J. W. L., Velazquez, E. R., Leijenaar, R. T. H., Parmar, C., Grossmann, P., Carvalho, S., Bussink, J., Monshouwer, R., Haibe-Kains, B., Rietveld, D., et al. (2014) · Nature Communications · doi:10.1038/ncomms5006 · Cited by 5,132 · cited 1×
“Radiomics is a high-throughput extraction of features from medical images using computer algorithms, aimed at providing quantitative information on tissue composition that otherwise cannot be detected through simple observation (102, 103).”
BackgroundCharoentong, P., Finotello, F., Angelova, M., Mayer, C., Efremova, M., Rieder, D., Hackl, H., & Trajanoski, Z. (2017) · Cell Reports · doi:10.1016/j.celrep.2016.12.019 · Cited by 5,041
Neoantigens in cancer immunotherapy
Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783
Determining cell type abundance and expression from bulk tissues with digital cytometry
Newman, A. M., Steen, C. B., Liu, C. L., Gentles, A. J., Chaudhuri, A. A., Scherer, F., Khodadoust, M. S., Esfahani, M. S., Luca, B. A., Steiner, D., et al. (2019) · Nature Biotechnology · doi:10.1038/s41587-019-0114-2 · Cited by 4,478
xCell: digitally portraying the tissue cellular heterogeneity landscape
Aran, D., Hu, Z., & Butte, A. J. (2017) · Genome Biology · doi:10.1186/s13059-017-1349-1 · Cited by 4,397 · cited 2×
“number of computational algorithms have been developed for the prediction of non-cancer cell infiltration (Table 1) (75, 79, 82, 85, 86, 88, 89).”
BackgroundTumor mutational load predicts survival after immunotherapy across multiple cancer types
Samstein, R. M., Lee, C.-H., Shoushtari, A. N., Hellmann, M. D., Shen, R., Janjigian, Y. Y., Barron, D. A., Zehir, A., Jordan, E. J., Omuro, A., et al. (2019) · Nature Genetics · doi:10.1038/s41588-018-0312-8 · Cited by 4,071
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
Ayers, M., Lunceford, J., Nebozhyn, M., Murphy, E., Loboda, A., Kaufman, D. R., Albright, A., Cheng, J. D., Kang, S. P., Shankaran, V., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci91190 · Cited by 3,788
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
Socinski, M. A., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodríguez-Abreu, D., Moro-Sibilot, D., Thomas, C. A., Barlesi, F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716948 · Cited by 3,733
Becht, E., Giraldo, N. A., Lacroix, L., Buttard, B., Elarouci, N., Petitprez, F., Selves, J., Laurent-Puig, P., Sautès-Fridman, C., Fridman, W. H., et al. (2016) · Genome Biology · doi:10.1186/s13059-016-1070-5 · Cited by 3,685
Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer
Paz-Ares, L., Luft, A., Vicente, D., Tafreshi, A., Gümüş, M., Mazières, J., Hermes, B., Çay Şenler, F., Csőszi, T., Fülöp, A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810865 · Cited by 3,617 · cited 1×
“In the randomized, phase III KEYNOTE 189 and KEYNOTE 407 trials, which involved patients with advanced non-squamous and squamous NSCLC, respectively, the addition of pembrolizumab to platinum-based chemotherapy resulted in improved outcomes in terms of response and survival over chemotherapy alone (5, 6).”
BackgroundApproaches to treat immune hot, altered and cold tumours with combination immunotherapies
Galon, J., & Bruni, D. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0007-y · Cited by 3,409
Mok, T. S. K., Wu, Y.-L., Kudaba, I., Kowalski, D. M., Cho, B. C., Turna, H. Z., Castro, G., Srimuninnimit, V., Laktionov, K. K., Bondarenko, I., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32409-7 · Cited by 3,303
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Topalian, S. L., Taube, J. M., Anders, R. A., & Pardoll, D. M. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.36 · Cited by 2,733
Comprehensive analyses of tumor immunity: implications for cancer immunotherapy
Li, B., Severson, E., Pignon, J.-C., Zhao, H., Li, T., Novak, J., Jiang, P., Shen, H., Aster, J. C., Rodig, S., et al. (2016) · Genome Biology · doi:10.1186/s13059-016-1028-7 · Cited by 2,451
The immune contexture in cancer prognosis and treatment
Fridman, W. H., Zitvogel, L., Sautès–Fridman, C., & Kroemer, G. (2017) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.101 · Cited by 2,263
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
Forde, P. M., Chaft, J. E., Smith, K. N., Anagnostou, V., Cottrell, T. R., Hellmann, M. D., Zahurak, M., Yang, S. C., Jones, D. R., Broderick, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716078 · Cited by 2,099
Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity
Veglia, F., Sanseviero, E., & Gabrilovich, D. I. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-020-00490-y · Cited by 1,940
Tertiary lymphoid structures in the era of cancer immunotherapy
Sautès-Fridman, C., Petitprez, F., Calderaro, J., & Fridman, W. H. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0144-6 · Cited by 1,884
Cancer immunoediting and resistance to T cell-based immunotherapy
O’Donnell, J. S., Teng, M. W. L., & Smyth, M. J. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0142-8 · Cited by 1,759
Reck, M., Rodríguez–Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.00149 · Cited by 1,670
Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC
Herbst, R. S., Giaccone, G., de Marinis, F., Reinmuth, N., Vergnenegre, A., Barrios, C. H., Morise, M., Felip, E., Andric, Z., Geater, S., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1917346 · Cited by 1,664
STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS -Mutant Lung Adenocarcinoma
Skoulidis, F., Goldberg, M. E., Greenawalt, D. M., Hellmann, M. D., Awad, M. M., Gainor, J. F., Schrock, A. B., Hartmaier, R. J., Trabucco, S. E., Gay, L., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0099 · Cited by 1,641 · cited 9×
“Several reports have demonstrated that tumors with a high TMB, like NSCLC, possess a high number of neoantigens.”
BackgroundInfluentialFinotello, F., Mayer, C., Plattner, C., Laschober, G., Rieder, D., Hackl, H., Krogsdam, A., Loncova, Z., Posch, W., Wilflingseder, D., et al. (2019) · Genome Medicine · doi:10.1186/s13073-019-0638-6 · Cited by 1,542
Simultaneous enumeration of cancer and immune cell types from bulk tumor gene expression data
Racle, J., de Jonge, K., Baumgaertner, P., Speiser, D. E., & Gfeller, D. (2017) · eLife · doi:10.7554/elife.26476 · Cited by 1,384
Rizvi, H., Sanchez-Vega, F., La, K., Chatila, W., Jonsson, P., Halpenny, D., Plodkowski, A., Long, N., Sauter, J. L., Rekhtman, N., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.3384 · Cited by 1,367
Paz-Ares, L., Ciuleanu, T.-E., Cobo, M., Schenker, M., Zurawski, B., Menezes, J., Richardet, E., Bennouna, J., Felip, E., Juan-Vidal, O., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30641-0 · Cited by 1,366
Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours
Galon, J., Mlecnik, B., Bindea, G., Angell, H. K., Berger, A., Lagorce, C., Lugli, A., Zlobec, I., Hartmann, A., Bifulco, C., et al. (2014) · The Journal of Pathology · doi:10.1002/path.4287 · Cited by 1,360
Conserved pan-cancer microenvironment subtypes predict response to immunotherapy
Bagaev, A., Kotlov, N., Nomie, K., Svekolkin, V., Gafurov, A., Isaeva, O., Osokin, N., Kozlov, I., Frenkel, F., Gancharova, O., et al. (2021) · Cancer Cell · doi:10.1016/j.ccell.2021.04.014 · Cited by 1,302 · cited 2×
“have developed a multi-omics and robust analytical platform to classify, reconstruct, and visualize the entire tumor composition (67).”
BackgroundAllele-Specific HLA Loss and Immune Escape in Lung Cancer Evolution
McGranahan, N., Rosenthal, R., Hiley, C. T., Rowan, A. J., Watkins, T. B. K., Wilson, G. A., Birkbak, N. J., Veeriah, S., Van Loo, P., Herrero, J., et al. (2017) · Cell · doi:10.1016/j.cell.2017.10.001 · Cited by 1,298
Personalized vaccines for cancer immunotherapy
Sahin, U., & Türeci, Ö. (2018) · Science · doi:10.1126/science.aar7112 · Cited by 1,147
Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy
Chowell, D., Morris, L. G. T., Grigg, C. M., Weber, J. K., Samstein, R. M., Makarov, V., Kuo, F., Kendall, S. M., Requena, D., Riaz, N., et al. (2018) · Science · doi:10.1126/science.aao4572 · Cited by 1,142 · cited 1×
“org 5 Resistance to ICI may also be driven by loss of antigen presentation occurring in antigen presenting cells or cancer cells within the TME, and is frequently associated with acquired genetic mutations, such as loss of heterozygosity (LOH) in HLA loci, mutation of HLA genes, and modulation of HLA gene expression (…”
BackgroundFrumento, G., Rotondo, R., Tonetti, M., Damonte, G., Benatti, U., & Ferrara, G. B. (2002) · The Journal of Experimental Medicine · doi:10.1084/jem.20020121 · Cited by 1,133
Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation
Dhatchinamoorthy, K., Colbert, J. D., & Rock, K. L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.636568 · Cited by 1,077
Advances in the development of personalized neoantigen-based therapeutic cancer vaccines
Blass, E., & Ott, P. A. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00460-2 · Cited by 1,042
Dieu-Nosjean, M.-C., Antoine, M., Danel, C., Heudes, D., Wislez, M., Poulot, V., Rabbe, N., Laurans, L., Tartour, E., de Chaisemartin, L., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.15.0284 · Cited by 1,031
Li, Y., Hermanson, D. L., Moriarity, B. S., & Kaufman, D. S. (2018) · Cell Stem Cell · doi:10.1016/j.stem.2018.06.002 · Cited by 981
Reck, M., Mok, T. S. K., Nishio, M., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodríguez-Abreu, D., Moro-Sibilot, D., et al. (2019) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(19)30084-0 · Cited by 946
Comprehensive evaluation of transcriptome-based cell-type quantification methods for immuno-oncology
Sturm, G., Finotello, F., Petitprez, F., Zhang, J. D., Baumbach, J., Fridman, W. H., List, M., & Aneichyk, T. (2019) · Bioinformatics · doi:10.1093/bioinformatics/btz363 · Cited by 928
The ectonucleotidases CD 39 and CD 73: Novel checkpoint inhibitor targets
Allard, B., Longhi, M. S., Robson, S. C., & Stagg, J. (2017) · Immunological Reviews · doi:10.1111/imr.12528 · Cited by 927
Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non–Small Cell Lung Cancer
Anagnostou, V., Smith, K. N., Forde, P. M., Niknafs, N., Bhattacharya, R., White, J., Zhang, T., Adleff, V., Phallen, J., Wali, N., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0828 · Cited by 896
Germain, C., Gnjatic, S., Tamzalit, F., Knockaert, S., Remark, R., Goc, J., Lepelley, A., Becht, E., Katsahian, S., Bizouard, G., et al. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201309-1611oc · Cited by 833
Gene expression markers of Tumor Infiltrating Leukocytes
Danaher, P., Warren, S., Dennis, L., D’Amico, L., White, A., Disis, M. L., Geller, M. A., Odunsi, K., Beechem, J., & Fling, S. P. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0215-8 · Cited by 806
CAR-NK cells: A promising cellular immunotherapy for cancer
Xie, G., Dong, H., Liang, Y., Ham, J. D., Rizwan, R., & Chen, J. (2020) · eBioMedicine · doi:10.1016/j.ebiom.2020.102975 · Cited by 800
Chauvin, J.-M., & Zarour, H. M. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000957 · Cited by 794
Sezer, A., Kilickap, S., Gümüş, M., Bondarenko, I., Özgüroğlu, M., Gogishvili, M., Turk, H. M., Cicin, I., Bentsion, D., Gladkov, O., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00228-2 · Cited by 789
Gettinger, S., Choi, J., Hastings, K., Truini, A., Datar, I., Sowell, R., Wurtz, A., Dong, W., Cai, G., Melnick, M. A., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0593 · Cited by 787
Kumagai, S., Togashi, Y., Kamada, T., Sugiyama, E., Nishinakamura, H., Takeuchi, Y., Vitaly, K., Itahashi, K., Maeda, Y., Matsui, S., et al. (2020) · Nature Immunology · doi:10.1038/s41590-020-0769-3 · Cited by 783
The future of cancer immunotherapy: microenvironment-targeting combinations
Murciano-Goroff, Y. R., Warner, A. B., & Wolchok, J. D. (2020) · Cell Research · doi:10.1038/s41422-020-0337-2 · Cited by 749
Ott, P. A., Hu-Lieskovan, S., Chmielowski, B., Govindan, R., Naing, A., Bhardwaj, N., Margolin, K., Awad, M. M., Hellmann, M. D., Lin, J. J., et al. (2020) · Cell · doi:10.1016/j.cell.2020.08.053 · Cited by 738
TIP: A Web Server for Resolving Tumor Immunophenotype Profiling
Xu, L., Deng, C., Pang, B., Zhang, X., Liu, W., Liao, G., Yuan, H., Cheng, P., Li, F., Long, Z., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0689 · Cited by 692
Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?
Ramjiawan, R. R., Griffioen, A. W., & Duda, D. G. (2017) · Angiogenesis · doi:10.1007/s10456-017-9552-y · Cited by 672
The Role of Angiogenesis in Cancer Treatment
Rajabi, M., & Mousa, S. (2017) · Biomedicines · doi:10.3390/biomedicines5020034 · Cited by 656
Koyama, S., Akbay, E. A., Li, Y. Y., Aref, A. R., Skoulidis, F., Herter-Sprie, G. S., Buczkowski, K. A., Liu, Y., Awad, M. M., Denning, W. L., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1439 · Cited by 640
Engineering CAR-T Cells for Next-Generation Cancer Therapy
Hong, M., Clubb, J. D., & Chen, Y. Y. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.07.005 · Cited by 639
Vanhersecke, L., Brunet, M., Guégan, J.-P., Rey, C., Bougouin, A., Cousin, S., Le Moulec, S., Besse, B., Loriot, Y., Larroquette, M., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00232-6 · Cited by 632
Prognostic Effect of Epithelial and Stromal Lymphocyte Infiltration in Non–Small Cell Lung Cancer
Al-Shibli, K. I., Donnem, T., Al-Saad, S., Persson, M., Bremnes, R. M., & Busund, L.-T. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0133 · Cited by 614
Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival
Brown, S. D., Warren, R. L., Gibb, E. A., Martin, S. D., Spinelli, J. J., Nelson, B. H., & Holt, R. A. (2014) · Genome Research · doi:10.1101/gr.165985.113 · Cited by 594
PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients
D'Incecco, A., Andreozzi, M., Ludovini, V, Rossi, E., Capodanno, A., Landi, L., Tibaldi, C., Minuti, G., Salvini, J., Coppi, E., et al. (2015) · British Journal of Cancer · doi:10.1038/bjc.2014.555 · Cited by 593
Profiling Cell Type Abundance and Expression in Bulk Tissues with CIBERSORTx
Steen, C. B., Liu, C. L., Alizadeh, A. A., & Newman, A. M. (2020) · Methods in Molecular Biology · doi:10.1007/978-1-0716-0301-7_7 · Cited by 566
CD40 agonist antibodies in cancer immunotherapy
Vonderheide, R. H. (2020) · Annual Review of Medicine · doi:10.1146/annurev-med-062518-045435 · Cited by 544
Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers
Caushi, J. X., Zhang, J., Ji, Z., Vaghasia, A., Zhang, B., Hsiue, E. H.-C., Mog, B. J., Hou, W., Justesen, S., Blosser, R., et al. (2021) · Nature · doi:10.1038/s41586-021-03752-4 · Cited by 543
Targeting the IDO1/TDO2–KYN–AhR Pathway for Cancer Immunotherapy – Challenges and Opportunities
Cheong, J. E., & Sun, L. (2018) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2017.11.007 · Cited by 487
Pesce, S., Greppi, M., Tabellini, G., Rampinelli, F., Parolini, S., Olive, D., Moretta, L., Moretta, A., & Marcenaro, E. (2017) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.04.025 · Cited by 465
Danaher, P., Warren, S., Lu, R., Samayoa, J., Sullivan, A., Pekker, I., Wallden, B., Marincola, F. M., & Cesano, A. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0367-1 · Cited by 421
Neutrophils dominate the immune cell composition in non-small cell lung cancer
Kargl, J., Busch, S. E., Yang, G. H. Y., Kim, K.-H., Hanke, M. L., Metz, H. E., Hubbard, J. J., Lee, S. M., Madtes, D. K., McIntosh, M. W., et al. (2017) · Nature Communications · doi:10.1038/ncomms14381 · Cited by 412
Lo Russo, G., Moro, M., Sommariva, M., Cancila, V., Boeri, M., Centonze, G., Ferro, S., Ganzinelli, M., Gasparini, P., Huber, V., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1390 · Cited by 408
Gevaert, O., Xu, J., Hoang, C. D., Leung, A. N., Xu, Y., Quon, A., Rubin, D. L., Napel, S., & Plevritis, S. K. (2012) · Radiology · doi:10.1148/radiol.12111607 · Cited by 398
Thommen, D. S., Schreiner, J., Müller, P., Herzig, P., Roller, A., Belousov, A., Umana, P., Pisa, P., Klein, C., Bacac, M., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0097 · Cited by 395
Tim-3 finds its place in the cancer immunotherapy landscape
Acharya, N., Sabatos-Peyton, C., & Anderson, A. C. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000911 · Cited by 394
Pende, D., Falco, M., Vitale, M., Cantoni, C., Vitale, C., Munari, E., Bertaina, A., Moretta, F., Del Zotto, G., Pietra, G., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01179 · Cited by 389
Tumor neoantigens: from basic research to clinical applications
Jiang, T., Shi, T., Zhang, H., Hu, J., Song, Y., Wei, J., Ren, S., & Zhou, C. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0787-5 · Cited by 386
Carrega, P., Morandi, B., Costa, R., Frumento, G., Forte, G., Altavilla, G., Ratto, G. B., Mingari, M. C., Moretta, L., & Ferlazzo, G. (2008) · Cancer · doi:10.1002/cncr.23239 · Cited by 379
Self-citationOrillion, A., Hashimoto, A., Damayanti, N., Shen, L., Adelaiye-Ogala, R., Arisa, S., Chintala, S., Ordentlich, P., Kao, C., Elzey, B., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0741 · Cited by 373
Prognostic Effect of Tumor Lymphocytic Infiltration in Resectable Non–Small-Cell Lung Cancer
Brambilla, E., Le Teuff, G., Marguet, S., Lantuejoul, S., Dunant, A., Graziano, S., Pirker, R., Douillard, J.-Y., Le Chevalier, T., Filipits, M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.0970 · Cited by 349
Liu, Y., Zugazagoitia, J., Ahmed, F. S., Henick, B. S., Gettinger, S. N., Herbst, R. S., Schalper, K. A., & Rimm, D. L. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1040 · Cited by 322
Stromal CD8+ T-cell Density—A Promising Supplement to TNM Staging in Non–Small Cell Lung Cancer
Donnem, T., Hald, S. M., Paulsen, E.-E., Richardsen, E., Al-Saad, S., Kilvaer, T. K., Brustugun, O. T., Helland, A., Lund-Iversen, M., Poehl, M., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-1905 · Cited by 312
Li, J., Wang, L., Chen, X., Li, L., Li, Y., Ping, Y., Huang, L., Yue, D., Zhang, Z., Wang, F., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1320011 · Cited by 299
Khorrami, M., Prasanna, P., Gupta, A., Patil, P., Velu, P. D., Thawani, R., Corredor, G., Alilou, M., Bera, K., Fu, P., et al. (2020) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-19-0476 · Cited by 297
Geospatial immune variability illuminates differential evolution of lung adenocarcinoma
TRACERx Consortium, AbdulJabbar, K., Raza, S. E. A., Rosenthal, R., Jamal-Hanjani, M., Veeriah, S., Akarca, A., Lund, T., Moore, D. A., Salgado, R., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0900-x · Cited by 286
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
(2018) · New England Journal of Medicine · doi:10.1056/nejmc1808251 · Cited by 277
Chetan, M. R., & Gleeson, F. V. (2021) · European Radiology · doi:10.1007/s00330-020-07141-9 · Cited by 265
Lin, A., Wei, T., Meng, H., Luo, P., & Zhang, J. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1062-7 · Cited by 264
VEGF may contribute to macrophage recruitment and M2 polarization in the decidua
Wheeler, K. C., Jena, M. K., Pradhan, B. S., Nayak, N., Das, S., Hsu, C.-D., Wheeler, D. S., Chen, K., & Nayak, N. R. (2018) · PLOS ONE · doi:10.1371/journal.pone.0191040 · Cited by 258
Shimizu, K., Nakata, M., Hirami, Y., Yukawa, T., Maeda, A., & Tanemoto, K. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181d60fd7 · Cited by 244
Rodriguez-Abreu, D., Johnson, M. L., Hussein, M. A., Cobo, M., Patel, A. J., Secen, N. M., Lee, K. H., Massuti, B., Hiret, S., Yang, J. C.-H., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.15_suppl.9503 · Cited by 244
He, D., Wang, D., Lu, P., Yang, N., Xue, Z., Zhu, X., Zhang, P., & Fan, G. (2021) · Oncogene · doi:10.1038/s41388-020-01528-0 · Cited by 238
Tamura, R., Tanaka, T., Akasaki, Y., Murayama, Y., Yoshida, K., & Sasaki, H. (2020) · Medical Oncology · doi:10.1007/s12032-019-1329-2 · Cited by 226
Higgs, B. W., Morehouse, C. A., Streicher, K., Brohawn, P. Z., Pilataxi, F., Gupta, A., & Ranade, K. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3451 · Cited by 220
Hwang, S., Kwon, A.-Y., Jeong, J.-Y., Kim, S., Kang, H., Park, J., Kim, J.-H., Han, O. J., Lim, S. M., & An, H. J. (2020) · Scientific Reports · doi:10.1038/s41598-019-57218-9 · Cited by 215
Paz-Ares, L., Kim, T. M., Vicente, D., Felip, E., Lee, D. H., Lee, K. H., Lin, C.-C., Flor, M. J., Di Nicola, M., Alvarez, R. M., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.03.003 · Cited by 205
The Role of Tumor Inflammatory Microenvironment in Lung Cancer
Tan, Z., Xue, H., Sun, Y., Zhang, C., Song, Y., & Qi, Y. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.688625 · Cited by 203
Akbay, E. A., Koyama, S., Liu, Y., Dries, R., Bufe, L. E., Silkes, M., Alam, M. M., Magee, D. M., Jones, R., Jinushi, M., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.04.017 · Cited by 198
He, B., Dong, D., She, Y., Zhou, C., Fang, M., Zhu, Y., Zhang, H., Huang, Z., Jiang, T., Tian, J., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000550 · Cited by 190
PD/1-PD-Ls Checkpoint: Insight on the Potential Role of NK Cells
Pesce, S., Greppi, M., Grossi, F., Del Zotto, G., Moretta, L., Sivori, S., Genova, C., & Marcenaro, E. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01242 · Cited by 187
Self-citationImmune Checkpoint Inhibitors in EGFR-Mutated NSCLC: Dusk or Dawn?
Qiao, M., Jiang, T., Liu, X., Mao, S., Zhou, F., Li, X., Zhao, C., Chen, X., Su, C., Ren, S., et al. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.04.003 · Cited by 186 · cited 1×
“EGFR mutated tumors have lower somatic mutations and number of neoantigens (60), display an uninflamed TME, which may explain the poor efficacy of ICI compared to EGFR-wild type (61).”
BackgroundDependence on the MUC1-C Oncoprotein in Non–Small Cell Lung Cancer Cells
Raina, D., Kosugi, M., Ahmad, R., Panchamoorthy, G., Rajabi, H., Alam, M., Shimamura, T., Shapiro, G. I., Supko, J., Kharbanda, S., et al. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-1050 · Cited by 178
Fumet, J.-D., Richard, C., Ledys, F., Klopfenstein, Q., Joubert, P., Routy, B., Truntzer, C., Gagné, A., Hamel, M.-A., Guimaraes, C. F., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0220-9 · Cited by 176 · cited 1×
“In addition, CD8+ TIL has also been described as a powerful biomarker in discriminating patients with a significantly longer PFS after ICI treatment; this association was strengthened when IS was integrated with tumor PD-L1 expression, suggesting that the combination of these markers could be a reliable biomarker for…”
BackgroundJia, T.-Y., Xiong, J.-F., Li, X.-Y., Yu, W., Xu, Z.-Y., Cai, X.-W., Ma, J.-C., Ren, Y.-C., Larsson, R., Zhang, J., et al. (2019) · European Radiology · doi:10.1007/s00330-019-06024-y · Cited by 172
Wesolowski, R., Sharma, N., Reebel, L., Rodal, M. B., Alexandra, P., West, B. L., Marimuthu, A., Severson, P. L., Karlin, D. A., Dowlati, A., et al. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919854238 · Cited by 169
Danilova, L., Anagnostou, V., Caushi, J. X., Sidhom, J.-W., Guo, H., Chan, H. Y., Suri, P., Tam, A., Zhang, J., Asmar, M. E., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0129 · Cited by 168
B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity
Yonesaka, K., Haratani, K., Takamura, S., Sakai, H., Kato, R., Takegawa, N., Takahama, T., Tanaka, K., Hayashi, H., Takeda, M., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-2852 · Cited by 167
Wu, S.-P., Liao, R.-Q., Tu, H., Wang, W., Dong, Z., Huang, S., Guo, W., Gou, L.-Y., Sun, H., Zhang, Q., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.11.132 · Cited by 163
Doi, T., Muro, K., Ishii, H., Kato, T., Tsushima, T., Takenoyama, M., Oizumi, S., Gemmoto, K., Suna, H., Enokitani, K., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1090 · Cited by 161
Lung Cancer Subtypes Generate Unique Immune Responses
Busch, S., Hanke, M. L., Kargl, J., Metz, H. E., MacPherson, D. P., & Houghton, A. M. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1600576 · Cited by 157
Tertiary lymphoid structures and B lymphocytes in cancer prognosis and response to immunotherapies
Jacquelot, N., Tellier, J., Nutt, S. L., & Belz, G. T. (2021) · OncoImmunology · doi:10.1080/2162402x.2021.1900508 · Cited by 157
nCounter® PanCancer Immune Profiling Panel (NanoString Technologies, Inc., Seattle, WA)
Cesano, A. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0088-7 · Cited by 156
A Burned-Out CD8+ T-cell Subset Expands in the Tumor Microenvironment and Curbs Cancer Immunotherapy
Sanmamed, M. F., Nie, X., Desai, S., Villarroel‐Espíndola, F., Badri, T., Zhao, D., Kim, A. W., Ji, L., Zhang, T., Quinlan, E., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0962 · Cited by 152
Lipson, E. J., Tawbi, H. A.-H., Schadendorf, D., Ascierto, P. A., Matamala, L., Gutiérrez, E. C., Rutkowski, P., Gogas, H., Lao, C. D., Janoski de Menezes, J., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.2021.39.15_suppl.9503 · Cited by 150
Thompson, J. C., Hwang, W., Davis, C. W., Deshpande, C. G., Jeffries, S., Rajpurohit, Y. R., Krishna, V., Smirnov, D. S., Verona, R. I., Lorenzi, M. V., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.10.012 · Cited by 149
Pembrolizumab plus allogeneic NK cells in advanced non–small cell lung cancer patients
Lin, M., Luo, H., Liang, S., Chen, J., Liu, A., Niu, L., & Jiang, Y. (2020) · Journal of Clinical Investigation · doi:10.1172/jci132712 · Cited by 149
Yi, M., Li, A., Zhou, L., Chu, Q., Luo, S., & Wu, K. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02817-z · Cited by 149
Targeting tumor‑associated macrophages in the tumor microenvironment (Review)
Zhou, K., Cheng, T., Zhan, J., Peng, X., Zhang, Y., Wen, J., Chen, X., & Ying, M. (2020) · Oncology Letters · doi:10.3892/ol.2020.12097 · Cited by 126
Yoon, H. J., Sohn, I., Cho, J. H., Lee, H. Y., Kim, J., Choi, Y., Kim, H. S., Lee, G., Lee, K. S., & Kim, J. (2015) · Medicine · doi:10.1097/md.0000000000001753 · Cited by 122
Natural killer cells in the human lung tumor microenvironment display immune inhibitory functions
Russick, J., Joubert, P.-E., Gillard, M., Torset, C., Meylan, M., Petitprez, F., Dragon‐Durey, M., Marmier, S., Varthaman, A., Josseaume, N., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001054 · Cited by 120
Ren, S., Xiong, X., You, H., Shen, J., & Zhou, P. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.689132 · Cited by 113
Weiss, S. A., Djureinovic, D., Jessel, S., Krykbaeva, I., Zhang, L., Jilaveanu, L. B., Ralabate, A. L., Johnson, B. J. B., Levit, N. S., Anderson, G., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0903 · Cited by 111
Radiomic Detection of EGFR Mutations in NSCLC
Rossi, G., Barabino, E., Fedeli, A., Ficarra, G., Coco, S., Russo, A., Adamo, V., Buemi, F., Zullo, L., Dono, M., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-0999 · Cited by 110
Self-citationxCell: Digitally portraying the tissue cellular heterogeneity landscapePreprint
Aran, D., Hu, Z., & Butte, A. J. (2017) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/114165 · Cited by 105
Li, R., Salehi‐Rad, R., Crosson, W. P., Momcilovic, M., Lim, R. J., Ong, S. L., Huang, Z. L., Zhang, T.-H., Abascal, J. W., Dumitras, C., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-3564 · Cited by 105
CAR T-cell therapy for lung cancer and malignant pleural mesothelioma
Zeltsman, M., Dozier, J., McGee, E., Ngai, D. A., & Adusumilli, P. S. (2017) · Translational research · doi:10.1016/j.trsl.2017.04.004 · Cited by 95
Wen, Q., Yang, Z., Dai, H., Feng, A., & Li, Q. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.620246 · Cited by 95
Regulatory T-Cells as an Emerging Barrier to Immune Checkpoint Inhibition in Lung Cancer
Principe, D. R., Chiec, L. S., Mohindra, N. A., & Munshi, H. G. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.684098 · Cited by 89
Edelman, M. J., Wang, X., Hodgson, L. C., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.3743 · Cited by 87
Harding, J. J., Patnaik, A., Moreno, V., Stein, M. N., Jankowska, A. M., de Mendizábal, N. V., Liu, Z. T., Koneru, M., & Calvo, E. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.8_suppl.12 · Cited by 86
Zammarchi, F., Havenith, K., Bertelli, F., Vijayakrishnan, B., Chivers, S., & van Berkel, P. H. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000860 · Cited by 85
Lin, S., Zhang, X., Huang, G., Cheng, L., Lv, J., Zheng, D., Lin, S., Wang, S., Wu, Q., Long, Y., et al. (2021) · Oncogene · doi:10.1038/s41388-020-01605-4 · Cited by 83
Emerging and multifaceted role of neutrophils in lung cancer
Aloe, C. A., Wang, H., Vlahos, R., Irving, L. B., Steinfort, D., & Bozinovski, S. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-760 · Cited by 82
Chen, Q., Zhang, L., Mo, X., You, J., Chen, L., Jin, F., Wang, F., Jin, Z., Zhang, B., & Zhang, S. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05509-7 · Cited by 82
Budczies, J., Kirchner, M., Kluck, K., Kazdal, D. N., Glade, J., Allgäuer, M., Kriegsmann, M., Heußel, C. P., Herth, F. J. F., Winter, H., et al. (2021) · OncoImmunology · doi:10.1080/2162402x.2020.1860586 · Cited by 80
Inhibitory Receptors and Immune Checkpoints Regulating Natural Killer Cell Responses to Cancer
Buckle, I., & Guillerey, C. (2021) · Cancers · doi:10.3390/cancers13174263 · Cited by 79
Ramalingam, S. S., Thara, E., Awad, M. M., Dowlati, A., Haque, B., Stinchcombe, T. E., Dy, G. K., Spigel, D. R., Lu, S., Iyer Singh, N., et al. (2022) · Cancer · doi:10.1002/cncr.33885 · Cited by 75
Zhang, C., Zhang, Z., Sun, N., Zhang, Z., Zhang, G., Wang, F., Luo, Y., Che, Y., & He, J. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1824641 · Cited by 75
Zhang, L., Chen, Y., Wang, H., Xu, Z., Wang, Y., Li, S., Liu, J., Chen, Y., Luo, H., Wu, L., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002356 · Cited by 73
Wang, S.-J., Khullar, K., Kim, S., Yegya‐Raman, N., Malhotra, J. D., Groisberg, R., Crayton, S. H., Silk, A. W., Nosher, J. L., Gentile, M. A., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000889 · Cited by 71
TIGIT negatively regulates inflammation by altering macrophage phenotype
Chen, X., Lu, P., Liu, L., Fang, Z., Wu, D., Liu, Z., Wang, C., Zhou, P., Yu, X., & He, W. (2015) · Immunobiology · doi:10.1016/j.imbio.2015.08.003 · Cited by 68
Zamarin, D., Hamid, O., Nayak-Kapoor, A., Sahebjam, S., Sznol, M., Collaku, A., Fox, F. E., Marshall, M. A., & Hong, D. S. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0328 · Cited by 68
Tang, J., Ramis‐Cabrer, D., Curull, V., Wang, X., Mateu-Jiménez, M., Pijuán, L., Durán, X., Qin, L., Rodríguez-Fuster, A., Aguiló, R., et al. (2020) · Cancers · doi:10.3390/cancers12092644 · Cited by 66
Bravaccini, S., Bronte, G., & Ulivi, P. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126536 · Cited by 64
Yoon, H. J., Kang, J. K., Park, H., Sohn, I., Lee, S.-H., & Lee, H. Y. (2020) · PLoS ONE · doi:10.1371/journal.pone.0231227 · Cited by 61
Phase 1 Expansion Cohort of Ramucirumab Plus Pembrolizumab in Advanced Treatment-Naive NSCLC
Herbst, R. S., Arkenau, H., Bendell, J. C., Arrowsmith, E. R., Wermke, M., Soriano, A., Penel, N., Santana-Dávila, R., Bischoff, H. G., Chau, I., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.10.004 · Cited by 60
Yang, B., Zhou, L. Q., Zhong, J., Lv, T., Li, A., Ma, L., Zhong, J., Yin, S., Huang, L., Zhou, C., et al. (2021) · Respiratory Research · doi:10.1186/s12931-021-01780-2 · Cited by 53
Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1
Smith, K. N., Llosa, N. J., Cottrell, T. R., Siegel, N. M., Fan, H., Suri, P., Chan, H. Y., Guo, H., Oke, T. F., Awan, A. H., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0492-x · Cited by 52
Trefny, M. P., Rothschild, S. I., Uhlenbrock, F., Rieder, D., Kasenda, B., Stanczak, M. A., Berner, F., Kashyap, A. S., Kaiser, M., Herzig, P., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3041 · Cited by 50
Immunotherapy for Unresectable Stage III Non–Small-Cell Lung Cancer
Rizvi, N. A., & Peters, S. (2017) · New England Journal of Medicine · doi:10.1056/nejme1711430 · Cited by 48
Vaccine and immune cell therapy in non-small cell lung cancer
Oliveres, H., Caglevic, C., Passiglia, F., Taverna, S., Smits, E., & Rolfo, C. D. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.05.134 · Cited by 45
Naing, A., Bauer, T. M., Papadopoulos, K. P., Rahma, O. E., Tsai, F. Y.-C., Garralda, E., Naidoo, J., Pai, S. G., Gibson, M. K., Rybkin, I. I., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz244.002 · Cited by 44
Zheng, Y., Tian, H., Zhou, Z., Xiao, C., Liu, H., Liu, Y., Wang, L., Fan, T. T., Zheng, B. J., Tan, F., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.651406 · Cited by 43
Li, L., Lu, G., Liu, Y., Gong, L., Zheng, X. Y., Zheng, H., Gu, W., & Yang, L. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.658690 · Cited by 39
Zeng, Z., Yang, F., Wang, Y., Zhao, H., Wei, F., Zhang, P., Zhang, X., & Ren, X. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1828538 · Cited by 37
Han, L., Shi, H., Luo, Y., Sun, W., Li, S., Zhang, N., Jiang, X., Gong, Y. Q., & Xie, C. (2020) · Cancer Medicine · doi:10.1002/cam4.3561 · Cited by 37
Grah, J. J., Katalinić, D., Juretić, A., Šantek, F., & Samaržija, M. (2014) · Tumori Journal · doi:10.1177/1430.15817 · Cited by 37
He, Y., Liu, S., Mattei, J., Bunn, P. A., Zhou, C., & Chan, D. C. F. (2018) · Drug Design Development and Therapy · doi:10.2147/dddt.s163304 · Cited by 35
Tumor antigens in human cancer control
Kelderman, S., & Kvistborg, P. (2015) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2015.10.004 · Cited by 29
Immunoscore Predicts Survival in Early-Stage Lung Adenocarcinoma Patients
Zhao, Z., Zhao, D., Ji, X., Wang, Y., & Wang, B. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00691 · Cited by 28
Natural Killers Are Made Not Born: How to Exploit NK Cells in Lung Malignancies
Carrega, P., & Ferlazzo, G. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00277 · Cited by 27
Self-citationKilvaer, T. K., Paulsen, E., Andersen, S., Rakaee, M., Bremnes, R. M., Busund, L., & Dønnem, T. (2020) · Carcinogenesis · doi:10.1093/carcin/bgaa105 · Cited by 26
Combined Immunoscore for Prognostic Stratification of Early Stage Non-Small-Cell Lung Cancer
Boscolo, A., Fortarezza, F., Lunardi, F., Comacchio, G. M., Urso, L., Frega, S., Menis, J., Bonanno, L., Guarneri, V., Rea, F., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.564915 · Cited by 16
Caushi, J. X., Zhang, J., Ji, Z., et al. (2021) · Nature · doi:10.1038/s41586-021-03893-6 · Cited by 14
Trentini, F., Mazzaschi, G., Milanese, G., Pavone, C., Madeddu, D., Gnetti, L., Frati, C., Lorusso, B., Lagrasta, C. A. M., Minari, R., et al. (2021) · Tumori Journal · doi:10.1177/03008916211000808 · Cited by 9
Cited by
Lung cancer immunotherapy: progress, pitfalls, and promises
Lahiri, A., Maji, A., Potdar, P. D., Singh, N., Parikh, P., Bisht, B., Mukherjee, A., & Paul, M. K. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01740-y · Cited by 1,102
Cords, L., Engler, S., Haberecker, M., Rüschoff, J. H., Moch, H., de Souza, N., & Bodenmiller, B. (2024) · Cancer Cell · doi:10.1016/j.ccell.2023.12.021 · Cited by 304
Shi, X., Hu, L., Huang, Y., Zhang, M.-F., Ying, X., Yuan, X., Wen, N., Lu, J., Zou, H., Tan, X., et al. (2026) · Journal of Advanced Research · doi:10.1016/j.jare.2025.09.014 · Cited by 6
Metadata
- Authors
- Genova, C., Dellepiane, C., Carrega, P., Sommariva, S., Ferlazzo, G., Pronzato, P., Gangemi, R., Filaci, G., Coco, S., & Croce, M.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2022-01-07
- Volume
- 12
- Pages
- 799455-799455
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W4206801412
- Cited by
- 260
- References
- 170
- FWCI
- 21.66
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.